Bayer Aktiengesellschaft (BAYN) Earnings Call Transcript & Summary

August 6, 2024

Deutsche Boerse Xetra DE Health Care Pharmaceuticals earnings 73 min

Earnings Call Speaker Segments

Jost Reinhard

executive
#1

Morning, everyone, and thanks for joining the call covering the second quarter of 2024. Bill is going to kick off the presentation by sharing how he sees business development and the headway we've made on our strategic objectives. After that, Wolfgang will go into greater detail on how operations performed during the second quarter and give his take on the outlook for the full year. Once the presentations wrap up, we'll move to Q&A, and Bill and Wolfgang will be joined by the presidents of our three divisions. Before we begin, I'd like to do what we always do and quickly point you to the cautionary language contained in our safe harbor statement. So with that, Bill, the floor is yours.

Bill Anderson

executive
#2

Okay, thank you, Jost, and thank you all for being with us. It is genuinely an honor to speak for Bayer's work today. During this next hour, my colleagues and I are going to walk through the progress achieved during the past quarter, and then we'll open things up for your questions. In that time, we hope you come away with a picture of what we see when we look at this company — an organization centered on the greatest challenges and opportunities that lie before us, one that is dedicated to delivering on what we promise and is moving forward in every area we laid out at our Capital Markets Day at the start of March. A key commitment we gave you that day is that this organization will deliver consistently while at the same time tackling the longer-term roadblocks that hold us back. The 154 days since March fifth offer pretty solid evidence that both are possible. Our business is competitive in every area. We're tearing down bureaucracy, we're intensifying our efforts on litigation, we're boosting cash generation, we're moving the pharma pipeline forward. Especially on that last point, you should see a lot of progress from us. Just yesterday, we received great news on Kerendia, which I'll come to later in my remarks.

Bill Anderson

executive
#3

There's still plenty of work ahead of us, but I'm pleased with the momentum we have, and we can say with confidence that Team Bayer is capable of meeting the challenge. Let's begin by examining how we performed operationally. The main takeaway here is that we continue to be on course to deliver. Our outlook for the group is confirmed. Revenues are up slightly on a currency- and portfolio-adjusted basis, and that's the basis we'll use throughout these remarks. Core earnings per share came in at EUR 3.76, and free cash flow went from -EUR 2.6 billion in Q1 to -EUR 1.4 billion at the half-year mark. I'll highlight a few key points from the divisions, and Wolfgang will walk you through the numbers in more detail and explain what's driving them. It's no secret that conditions in the agriculture market have been difficult. We've felt that too, but our Crop Science business nearly offset the headwinds through corn pricing, along with higher soybean and glyphosate volumes. We faced margin pressure in the first half, yet our team has been disciplined about recovering costs and improving inventories to strengthen our cash generation across the first half of the year, and we'll keep that a priority in the second half. Pharma delivered another very solid quarter in Q2.

Bill Anderson

executive
#4

There's solid momentum across the team, and I've been impressed with the way the LOE transition is being handled. Xarelto was down 11% in Q2, and that's not a major shock, considering the growing generic pressure. Meanwhile, our launch products Nubeqa and Kerendia keep up their impressive momentum, with sales for each rising 70% or more year to date. Eylea is expanding in every region, and the 8-milligram launch is underway in the first markets. Our base business has shown itself to be robust. In fact, leaving out the Xarelto business, pharma sales would have risen 9% in Q2 and 7% in the first half of the year. Growth of that kind would put us at the upper end of the industry. Year over year, we expanded our margin in the first half of 2024, despite headwinds from an unfavorable product mix, currencies, and the higher costs tied to launches. Consumer Health went back to growth in Q2, lifting H1 sales to a 2% increase, with most categories up. We're seeing great growth out of our dermatology category, thanks largely to the Bepanthen brand family. And I've heard directly from pharmacists in Europe that they're very pleased about supply improvements for Iberogast, which is driving growth in our digestive health category.

Bill Anderson

executive
#5

Our EBITDA margin was 22.3%. With these results, we're in a solid position to reaffirm the guidance for the full year. There's still a great deal left to do, but we'll keep building on the momentum we have, quarter after quarter. On behalf of all my colleagues and everyone on Team Bayer, I can say we know what has to be done to deliver, and that is exactly what we intend to do. Now, let's turn to our strategic priorities. First up, growth and innovation. A lot is happening in our pharma pipeline. We'll get into that shortly on a dedicated slide, but I also see important developments in the other divisions. In crop science, we're continuing the rollout of Short Stature Corn. It's in the ground in fields across the United States, with pilots under way in Italy and Spain. Yet that isn't the only innovation we have going in corn. This year, we launched a new generation of VT4PRO corn in the U.S. This technology helps the corn plant defend itself against the corn rootworm, one of the most perilous pests in agriculture... With a demonstrated yield advantage of more than 5 bushels per acre, we expect it to reach up to 1 million acres in its first year on the market.

Bill Anderson

executive
#6

When it comes to consumer health, we've set out a vision of reaching billions of consumers with trusted self-care. That represents a step change from where we stand today, and achieving it will call for quality growth driven by innovation, by expanding new brands, and by making the right portfolio choices. That's the reason we're taking brands such as Iberogast, a beloved gut health treatment, and expanding it into the U.S. We're launching One A Day into the emerging field of cellular health. Now turning to litigation. On PCBs, we had some news at the end of July that I'd like to put in context. You might recall that in 2020, we communicated a nationwide class settlement with 2,500 local governments. Some municipalities opted out. Seattle was one of them. A unique case with special circumstances, as it involved claims not present in the other opt-outs. So reaching a settlement here is significant. Overall, there are nine environmental cases involving municipal plaintiffs that are still pending, and each case is different. If we choose to pursue settlements, we expect them to come in at lower terms. Beyond that, we've ramped up our efforts to enforce the indemnity agreements signed with Monsanto. In the Roundup litigation, we achieved a very favorable decision from Down Under, where the Federal Court of Australia dismissed a class action.

Bill Anderson

executive
#7

To repeat what I said before: when the argument truly hinges on the science presented in court, we come out ahead. In the U.S. as well, we've observed encouraging signs. Take the Philadelphia Court of Common Pleas — for corporate defendants in America, that is the toughest venue there is — yet in the latest Roundup matter, rulings came down on our side, and in the end that is what pushed the plaintiff to drop the suit. That, in our view, counts as a major win. Beyond the courtroom, we keep looking at ways to limit our exposure to litigation. Part of that means working alongside farmers in America, who recognize how essential glyphosate is both to their own livelihoods and to feeding the world. Our attention remains on legislative efforts at the state level and at the federal level, and that includes pushing for Congress to pass a Farm Bill at the earliest opportunity. What we're after is a bill delivering the certainty and the science-based oversight that American farmers are owed. Their voices will keep having our support. On top of that, we keep assessing every suitable step that could bring this matter to a close — for our company and for farmers in the U.S. alike — since our revenue needs to fund the company's mission rather than the litigation industry. Third, cash. We are making progress toward our goal of EUR 2 billion-3 billion in free cash flow for this year.

Bill Anderson

executive
#8

We observed impacts from reduced incentive payments during Q2. In addition, we're placing significant emphasis on inventory management and on optimizing working capital. You should expect further progress on that front in the second half. And lastly, dynamic shared ownership. Julio and his team unveiled the architecture for our consumer health division two weeks ago. They are merging roles and stripping out multiple layers to sharpen focus, amplify impact, and better integrate the consumer into how we work. We have broadened what leadership roles cover — merging our head of R&D with head of marketing, for instance. Regions have been consolidated. We are widening the span of coaching. Those are bold calls, and more of them will follow. Each of our three businesses now has an organizational blueprint that is leaner, less hierarchical, more centered on customers and products, and will keep improving against that benchmark, with the aim of aligning everything with the mission. A new operating approach is being methodically rolled out across the entire company, and it is moving quickly. The company has 3,200 fewer jobs than at the start of the year, and 900 teams have been set up to work on some of our most important missions. Our new Berocca team has been fully trained in the new model, and that business is growing across all regions, beating expectations, both quarter-over-quarter and year to date.

Bill Anderson

executive
#9

Our crop science group intends to launch 10 blockbusters across the coming decade, and those 10 teams sit within the 50 product teams we have activated in crop science, every one of them focused solely on bettering the solutions we create for farmers around the globe. Now, I have just alluded to how our pharma pipeline is progressing. Let's examine it more closely. During the last 90 days alone, we have made major strides in filling the mid-stage pipeline, broadening labels, and moving late-stage assets forward. I'll begin with the latest news we have on Kerendia. Only yesterday, we announced positive top-line data from the phase III trial, FINEARTS-HF. That is significant news, particularly in a business as high-stakes and innovation-driven as ours. And we are glad to report that all of our last five phase III clinical trials have produced successful outcomes. This trial assesses the medicine in patients who have heart failure, with a left ventricular ejection fraction of 40% or greater. Let me give that some context. Heart failure ranks as the top cause of hospitalization among people over 65. Mortality rates are comparable to, or even worse than, those of most common cancers. Among the 60 million people worldwide who suffer from heart failure, roughly half meet the parameters this study evaluated.

Bill Anderson

executive
#10

We’re eager to present the full details from this trial in under 4 weeks, at the European Society of Cardiology Congress taking place on September 1. Our hope is that these findings may substantially broaden the group of patients we can serve with Kerendia. Progress is also being made on Parkinson’s, a devastating condition that for far too long has lacked meaningful improvements in standard care. AB-1005, a gene therapy intended to treat this disease, received Fast Track designation from the FDA. That therapy additionally earned the Innovation Passport, the UK MHRA’s Innovative Medicine Designation. A phase II trial involving 87 patients is currently running, and this is already the second investigational gene therapy from AskBio to get to mid-stage clinical development. Beyond that, the FDA granted a Regenerative Medicine Advanced Therapy designation to bemdaneprocel. Among investigational cell therapies in the U.S. for Parkinson’s disease, bemdaneprocel is the most clinically advanced. It could help people living with Parkinson’s recover functions lost to this terrible disease. Lastly, we are developing an investigational tyrosine kinase inhibitor for patients with non-small cell lung cancer whose tumors carry HER2 mutations.

Bill Anderson

executive
#11

The FDA's Breakthrough Therapy designation was recently granted to this work. Our phase I results proved so encouraging that we could move the program straight into late-stage development, and we're on the verge of enrolling the first patient in a phase III trial. In addition to these pipeline advances, we're seeing solid commercial momentum across our portfolio. Positive top-line results from the ARANOTE study came in mid-July, and that has let us further strengthen the data package supporting Nubeqa's clinical profile. We anticipate these data will open the door to a broader label in the metastatic hormone-sensitive setting of prostate cancer, which would now include using the medicine without concomitant chemotherapy. As we look toward 2025, we're getting ready to launch two products: elinzanetant, a potential novel non-hormonal option for women dealing with vasomotor symptoms tied to menopause, and acoramidis, a cardiology drug for which we hold exclusive marketing rights in Europe. We recently filed elinzanetant for regulatory review in the U.S., and acoramidis was filed in Europe back in January of this year. Since then, new data from the ATTRIBUTE-CM trial, presented in May, confirmed the medicine's potential for a best-in-class clinical profile. Our pharma pipeline stands among our greatest levers for creating value.

Bill Anderson

executive
#12

There is definitely a great deal still to accomplish here, but 2024 has been quite productive, and we have reason to feel optimistic about what lies ahead. Now, before I pass things over to Wolfgang, I'd like to wrap up my comments by taking a look at what's left in the year. As I mentioned earlier, some work remains before we reach our targets. Let me reassure you that our attention is firmly fixed on this, and we will deliver. Here are several priorities on which we're concentrating across every business. In pharma, we intend to capitalize fully on our growth opportunities. You should expect us to continue building the EYLEA growth story, driven in part by the ongoing rollout of the 8 mgs. And we will keep expanding our Nubeqa and Kerendia franchises. In crop science, we anticipate robust growth in our core, especially from our core crop protection business, including innovative products such as the Fox family and Curbix in Latin America. Beyond that, we are managing our costs with great care, and we are evaluating how best to respond to mounting pricing pressure from generic crop protection. Our belief is that this will demand a tailored approach, much like how we handle glyphosate today. We keep exploring options to mitigate the price pressures we're seeing in crop protection.

Bill Anderson

executive
#13

Beyond that, we aim to widen our margins during the latter half of the year, with Dynamic Shared Ownership as a key lever. In consumer health, we'll generate demand and speed up growth by way of effective launches and science-based innovation. Each of these priorities will be pursued in the near term, even as we keep tackling our longer-term challenges. Earning back trust requires us to do both, and I know we have what it takes. So thank you for your attention, and I'll hand things over to Wolfgang.

Wolfgang Nickl

executive
#14

Thanks, Bill, and hello from me as well. Before I move to our full-year outlook, I want to give a little more detail on what drove our second quarter results. So let's start with the group results. On a currency- and portfolio-adjusted basis, Q2 sales rose 3% to EUR 11.1 billion. We had a EUR 240 million foreign exchange headwind. As a result, sales growth as reported came in at roughly 1%. EBITDA before special items reached EUR 2.1 billion, which is 16%, or about EUR 420 million, under the prior year quarter. The main drivers were an unfavorable mix effect in crop science and a higher provision for short-term incentives versus a significant reversal in the prior year quarter. We also had roughly EUR 130 million of FX headwinds within EBITDA before special items. All in all, the margin before special items at the EBITDA level was 18.9% for the quarter. That lower EBITDA before special items led to core earnings per share of EUR 0.94 in Q2, down EUR 0.28, or about 23%, from the prior period. Our core financial result was -EUR 0.5 billion, in line with the prior year quarter.

Wolfgang Nickl

executive
#15

Even though earnings were lower, free cash flow reached EUR 1.3 billion, versus a negative EUR 0.5 billion in Q2 of last year. Two big factors produced that gain. Thanks to active working capital management, we converted more of our earnings into cash. Our Q2 Free Cash Flow, for example, reflects positive results from efforts to optimize inventory. On top of that, incentive payouts were lower than a year earlier by roughly EUR 1 billion. That positive cash contribution in the quarter brought net financial debt down to EUR 36.8 billion by the close of Q2. I'll now walk through divisional performance on behalf of my colleagues. In a market where overall growth is much softer than expected at the start of the year, Crop Science sales reached EUR 5 billion in Q2, up 1% from a year earlier. Our core business fell by 3%, mainly because of fewer corn acres, unfavorable weather, and generic pricing pressure in core crop protection. Still, we managed to offset part of that with growth in our soybean business, which gained from higher volumes thanks to acreage expansion in North America. Beyond that, our insecticide franchise posted strong volume growth, largely from our Movento product in EMEA.

Wolfgang Nickl

executive
#16

When it comes to corn, we keep seeing robust pricing around the world, and that's thanks to the outstanding performance our portfolio delivers. Our glyphosate business posted 42% sales growth, with volumes rising because shipping patterns returned to normal, while prices stayed mostly in line with historical averages. As a reminder, the prior year quarter was hit by general inventory destocking, drought conditions, and volatile prices in the market, which pushed purchases into the second half of 2023. On profitability, our EBITDA before special items reached EUR 524 million, at a margin of 10.5%. The significant decline versus the prior year was driven equally by an unfavorable product mix and higher short-term incentive provisions. LatAm was driven by a significant reversals of provisions in Q2 of last year's that I already mentioned. The main drivers of the mix effect were much higher volumes of Glyphosate, coupled with lower corn and fungicide volumes. On the positive side, we are beginning to see some COGS recovery in the quarter, led by lower crop protection raw material costs. Positive currency effects also helped to offset some of the headwinds. Let's now move on to our pharma business, which again grew 4%. Prices were up 3% and volumes were up 1%.

Wolfgang Nickl

executive
#17

The strong results from our launch products and from EYLEA offset—in fact, more than offset—the greater pressure we saw on Xarelto. On top of that, our base business made a positive contribution. That includes, for instance, the radiology and women's health businesses, which turned in a robust performance despite the persistent headwinds we face in China tied to volume-based procurement there. Our launch assets, Nubeqa and Kerendia, showed continued strong growth momentum. Nubeqa nearly doubled its sales once again and, on a moving annual total basis, reached blockbuster status. Kerendia passed the EUR 100 million per quarter threshold for the first time, mainly on the back of higher volumes in both the United States and China. EYLEA also added to the overall increase, with gains across all regions. Although that dynamic was still mostly driven by the solid performance of the 2-milligram formulation in Japan and Canada, the 8-milligram launch picked up further momentum. Let me go into a bit more detail on Xarelto. We posted sales declines of 11%. As expected, the loss of patent protection in Canada and of the compound patent in Europe brought on generic pressure. In Europe, we are dealing with legal disputes over the once daily intake patent, since generic manufacturers are contesting our IP position country by country.

Wolfgang Nickl

executive
#18

We've won every first-instance decision on patent validity up to now, with the exception of the United Kingdom and France. That led to generic at-risk launches in those two markets during the second quarter... Even though first-instance disputes remain ongoing across most European countries, that didn't stop generic competitors from launching at risk there either. We observed this, for example, in Switzerland and Poland. We've incorporated generic headwinds into our 2024 guidance for Xarelto, and naturally we'll keep taking vigorous action against any infringement of our IP rights. Turning to profitability, EBITDA before special items reached EUR 1.3 billion, a 4% decrease compared with the prior-year quarter. Here too we saw higher incentive provisions following the reversal already mentioned from the prior year. Beyond that, we booked a 220 basis point FX headwind along with unfavorable product mix changes, driven by the Xarelto sales decline. Stringent OpEx management and resource shifts largely offset these effects. Now, on Consumer Health, Q2 sales performance returned to growth as expected. Sales rose 5% versus the prior year. We grew sales in nearly every category, continuing to deliver superior innovation to the market.

Wolfgang Nickl

executive
#19

Along with a better supply picture, we delivered 15% growth in digestive health, which was our strongest category in the quarter. Our allergy and cold business fell, mainly because the allergy season was weak. On top of that, we kept facing headwinds from lower volumes, as retailers in the United States went on optimizing their inventories across the industry. Even so, targeted price management let us mitigate those downsides. On the bottom line, EBITDA before special items reached EUR 314 million, with a margin of 21.5%. A continued focus on cost and price management could partly offset the increased investment in our innovative products and launches. Moving now to the divisional full year outlook. With the first six months behind us, we have better visibility for the full year. So let me talk a little bit about the business drivers for each one of the divisions, and I'll start with Crop Science. Given the market-driven headwinds, we now expect our Crop Science division to come in at the lower end of our sales growth and margin guidance. For the second half of the year, we expect strong growth in our core business to be muted by significant volume declines in glyphosate, following the phasing patterns we saw in 2023.

Wolfgang Nickl

executive
#20

When it comes to profitability, growth in the core business, COGS recovery, DSO and other efficiency savings should offset inflation and merit increases. That will produce wider margins than in the second half of the prior year. We also revised our FX estimate using June-end spot rates. Against the March-end spot rates, we now expect a bigger currency headwind for Crop Science, and that applies to sales, at roughly 2 percentage points versus approximately 1 percentage point before. Turning to Pharma. Given the good performance in half year one, we expect year-on-year sales growth of between 0% and 3% for the full year. As a reminder, that is up from the previous -4% to 0%. For the rest of the year, we anticipate mounting pressure on Xarelto. Ongoing strong performance from our launch assets and EYLEA should partially offset this headwind. For EYLEA, we expect low single-digit % sales growth for the full year. Our guidance on EBITDA margin before special items stays unchanged, showing a sequential margin decline in half year two versus half year one, driven largely by an unfavorable product mix and continued investments in launches, as well as R&D investments in our pipeline.

Wolfgang Nickl

executive
#21

On the Consumer Health side, we are reaffirming the guidance for the full year at constant currencies. Growth should pick up pace during the second half, powered by innovation and targeted pricing, along with additional improvements in our supply situation. Cost pressure persists, and it is weighing on profitability. Along with greater operational efficiencies, focused price management, and fast implementation of DSO, we are working actively to offset those effects. Now let's turn, finally, to the group outlook. For the group, we reaffirm the full year guidance. FX group estimates, based on June-end spot rates, are unchanged from the March-end spot rates used before. Our other modeling considerations likewise remain as previously guided, as shown in the appendix to our presentation. That brings our prepared remarks to a close, and Jost, back to you to moderate the Q&A, please.

Jost Reinhard

executive
#22

Much appreciated, Wolfgang and Bill, for those presentations. That brings us to the Q&A portion, and I'd also like to welcome Stefan, who is here with us in the room, along with Rodrigo and Julio, joining us on their screens from headquarters. Just a few housekeeping notes before we start. Should you have a question, kindly raise your hand and follow the instructions in the chat. Remember to unmute yourselves before posing your questions, and please keep your contribution to two questions so that more participants can be accommodated in the session. Today's first question comes from Vincent Andrews of Morgan Stanley. Vincent?

Vincent Andrews

analyst
#23

Thanks. Morning, everyone. Rodrigo, two things I'd like your help with. First, where do you figure U.S. corn planted acreage ended up this year? And within that number, do you believe you gained share or lost share? Second, looking toward the back half, could you walk us through how you see corn acres playing out — both in Argentina, given the corn stunt problems, and in Brazil, where there may be some headwinds from weaker corn prices? Thank you.

Rodrigo Santos

executive
#24

Thank you, Vincent. I'll begin with the U.S. So in the U.S., we once again had a solid showing from our corn this year. We're coming off a really strong global performance last year. Our corn business is putting up another strong result. Of course, we did see corn acreage in the U.S. come down by 3 to 4 million acres. We'll see how this season ends up. It's worth noting that, as you know, we begin selling in North America in Q4 of last year, and then this is plus Q1 and Q2. We feel confident about our share. We conducted a lot of research with farmers, and we will keep seeing our genetic market share above 50%, and our trade share in corn in the U.S. above 80%. So a great performance on corn, which we're seeing here. Turning to South America, right now you're seeing the effect of the corn stunt, as you mentioned, in Argentina — a bit more challenging in Argentina. In Brazil, the commodity price has an impact, but the currency is also helping farmers a little right now, and we see a higher area of corn.

Rodrigo Santos

executive
#25

Nothing major, Vincent, though corn makes up a larger portion of the summer and Safrinha mix in Brazil. So on the whole, I’d describe our global corn results as very strong. The same holds true in North America. I want to call that out since you gave me the opening. In the U.S., we’ll sit above 50% genetic share and above 80% trade share. And as Bill noted, we introduced VT4PRO this year, and in its first launch year we’ll reach nearly 1 million acres. So we’re very pleased with seed performance, particularly in corn, as you requested. Thank you.

Jost Reinhard

executive
#26

Thanks, Rodrigo. Up next we have Peter Verdult of Citigroup, followed by Sachin Jain from Bank of America. Peter, go ahead.

Peter Verdult

analyst
#27

Thank you. This is Peter Verdult from Citi, with a couple of questions, please, for Stefan. It's really good to see FINEARTS-HF achieve its primary endpoint. I understand you're unable to discuss the specific data, but could you at least give us some context, since the market has recently seen other positive heart failure datasets from parties such as numerous GLP-1 agonists and SGLT2? So anything that helps us gauge your confidence when FINEARTS-HF data is placed alongside what we're seeing elsewhere in heart failure would be helpful. Please don't simply advise me to be patient and wait until the ESC. Second, Rodrigo, this question comes from a farmer analyst. It appears you're leaning more and more on a strong Q4 from LatAm in order to meet the guidance. So it's a two-part question. Jost, is the guidance coming down mainly due to what you're observing in corn and fungicide dynamics? If not, what else is involved? And what exactly gives you confidence that these strong volumes will come through as we head into 25? Thank you.

Stefan Oelrich

executive
#28

Thanks for that question, Pete. I share your enthusiasm here, since this is a space where more studies have failed than succeeded, and we're genuinely very excited about hitting the primary endpoint along with some secondaries in this setting. Now, regarding comparisons with other agents such as SGLT2s or GLP-1s, please keep in mind the kind of population we're studying. A lot of people receive these medicines in hospital. So GLP-1 may not necessarily be the right comparator, but obviously we've also seen in the study a portion — and I think you know this from a baseline — of patients who had been put on SGLT2s beforehand. So to some degree we'll be able to compare the effect of product on top of SGLT2 and product in a single setting. And again, let me remind you this is a very sick patient population. Also keep in mind that this is only the first of many studies we've put up in heart failure. We have what we call the MOONRAKER program, which will begin somewhere next year. So we're really excited about creating a great new option for patients in heart failure.

Stefan Oelrich

executive
#29

Then there are just about 3 or 4 weeks left before the data get presented at ESC. So take a summer vacation, and once you're back, the expected results will be there for you to see. We also expect to get this published in a top-tier journal. And as for everything else, yes, we're genuinely excited about this.

Rodrigo Santos

executive
#30

Appreciate that, Peter, for the crop science question. Let me give you some data on that. In the second half of the year, largely driven by LatAm and Asia, plus the start of next season in North America too. We're already into Q4 for North America. Putting that together, much like last year — I recall on this call a year ago we said we'd deliver 7% growth in our core business, and we delivered 6.7% growth in our core business. Along those same lines, we anticipate, yes, a strong performance in LatAm... a few factors, and we've done very well across LATAM in recent years relative to the industry. Main reasons for that: many of the launches we've had — Bill touched on some of them. The Fox family, where we hold the leading fungicide position in the market. Curbix, where we're growing substantially in the insecticide market as well, and our strong standing in both soybean and corn, plus the growth we have. Considerable innovation and the new operating model already running there, driving the results we're seeing.

Rodrigo Santos

executive
#31

Sure, I’d say we delivered a solid performance in the core during the second half of the year. Let me take your question as a chance to walk through a bit of the moving parts. We’ll have Q3 and Q4. For Q3, we expect sales to decline less sharply, given the glyphosate volume dynamics that Wolfgang referred to. In the core, we’re seeing modest growth in Q3 and stronger growth in Q4, reflecting the markets we serve. Thanks for your question.

Stefan Oelrich

executive
#32

Okay, Sachin, the floor is yours now.

Sachin Jain

analyst
#33

I appreciate that.

Stefan Oelrich

executive
#34

Go ahead, please.

Sachin Jain

analyst
#35

Hello, and thank you for taking my question. This is Sachin Jain from Bank of America. I have two questions for Stefan, if I may, both on the financial side. First, regarding the upgrade to the pharma sales guidance: the only product you explicitly mentioned in your introductory remarks, I believe, was EYLEA. So I'd appreciate some additional color on how you're viewing Xarelto, along with expectations for 2H — earlier in the year there was commentary that you would provide clarity on the rate of decline in 2H versus 1H — and also on how sustainable the Nubeqa growth is, given how strong it was in the second quarter. My second question concerns 2H pharma margins. Is the 2H margin, which is in the mid-twenties, a better proxy for thinking about full year 2025? We're simply trying to gain a clearer sense of how sustainable the launch costs and R&D costs are that you're incurring in the back end of this year and continuing into next year. Thank you.

Stefan Oelrich

executive
#36

Okay, I tallied up several questions there. So with EYLEA, the first half has been strong, in terms of both volume and a bit of price improvement. That's also reflected in the 8 milligrams launch, which is off to a robust start. We don't anticipate that shifting. So overall, EYLEA should see growth in the low single digits for the year. On Xarelto, the second half is clearly now affected by some of those generic launches you heard about, in the U.K. and France. Those will be more compounded, so to speak, once you factor in the full-year effect. So compared with the first half, we're looking for a larger decline in the second half. Regarding Nubeqa's durability, keep in mind that with ARASENS we gained one more proof point. So at this point, in principle, we hold data spanning the entire spectrum of prostate cancer. And I'd say that's further evidence of Nubeqa increasingly becoming a standard of care, and the numbers show it. So our prescriber base is wider, and repeats within our existing prescriber base are higher as well. So this truly isn't a one-quarter phenomenon. On overall sales, perhaps let me restate some of the guidance I provided at Capital Markets Day for our launch products, which should be able to offset what we view as Xarelto losses until the LOE as a whole essentially reaches a standstill.

Stefan Oelrich

executive
#37

And we're now seeing meaningful proof points that actually confirm that top-line outlook. On our 2025 margins, you're 100% right. So we have several launches ahead. We keep, obviously, investing in Kerendia now, with the additional indication expected next year. We'll keep investing in EYLEA with the 8 milligrams launch, and the same on prostate cancer, and add elinzanetant to that, which we submitted and which will launch in the second half of next year. So it's a lot of launches coming together, which places some burden on our SG&A. We're trying to manage this through very tight cost control. I think you can see in the first half that we've been really good at managing our costs despite a number of headwinds, and we continue to do so. But obviously, when Xarelto is stronger, that has an impact on our overall gross margin. So we expect somewhat deteriorating margins in the second half. At Capital Markets Day, we guided for the midterm that our pharma margins are targeted at constant exchange rate in the mid-twenties. I have no reason to change this at this point, unless we continue to see such a positive performance by our launch brands, but that's not for this quarter.

Stefan Oelrich

executive
#38

I appreciate that.

Jost Reinhard

executive
#39

Great. Thanks. Then our next questioners are Christian Fais at Kepler Cheuvreux and Emily Field at Barclays. Christian, go ahead first, please.

Rodrigo Santos

executive
#40

Yes, sir. Thank you, Jost, and thanks for fielding my two questions. To start with consumer health: why is North America still posting such persistently sluggish growth? In your report you mention customer destocking — is that happening at the wholesale level, at retail, with the end consumer, or across all three? Then secondly, on corn, please. Corn is midway through production for next year, so what acreage figure do you expect for Short Stature Corn in 2025? Thanks very much.

Stefan Oelrich

executive
#41

All right. Julio, would you like to handle that first question?

Julio Triana

executive
#42

Absolutely, and thanks, Christian, for that question. Yes, you're correct — it's all 3 of them. But the main impact we're seeing, you know, comes from inventory adjustments at our retail partners. And we saw that very strongly in Q1, and to a lesser extent — or, you know, it's sort of beginning to normalize in Q2 — but we do expect that correction to play out over the entire year. On the volume side, that has affected, you know, our business in the U.S. The other impact related to an allergy season that was much weaker than we had anticipated, and the same thing with the cough and cold season. So those are basically the main drivers there.

Stefan Oelrich

executive
#43

Thanks. Rodrigo, over to you?

Rodrigo Santos

executive
#44

Sure. Regarding Short Stature Corn, we're really enthusiastic. I was in Spain with farmers not long ago, and we're also seeing how it's making a difference in Europe. But back to North America — the experience from farmers has been excellent. Christian, it's still 2025. There's no material financial impact yet, since our expansion is built on the breeding of Short Stature Corn. A key element for us is the launch of the biotech version, which will come with what we call the 10 blockbusters we're launching in 2027 and beyond. At that point we can greatly broaden what's offered to farmers, and it could become truly material. So it remains 2025. Much of this is about expanding thousands of acres of farmers using short stature corn, but on the financial side the impact isn't major, because we expect that expansion to come with the biotech version down the road. We're also making progress in South America on that one, and we expect short stature corn to have a global impact in Asia as well, and this will change how farmers grow corn going forward. So we're very excited about it.

Christian Faitz

analyst
#45

All right, many thanks.

Jost Reinhard

executive
#46

Great. Emily, you’re next.

Emily Field

analyst
#47

Hi, thank you for taking my questions — I have one about pharma and one about crop. On the pharma side, I was hoping you could share how the business is doing on an underlying basis in China. I realize you've had some recovery from the COVID effects of last year, but clearly certain competitors, especially in vaccines, have mentioned possibly softer demand in that region. So I'd just like your general thoughts on how the business is performing there. Then on crop, I realize it's somewhat early, but we're now past the glyphosate pricing reset, and this year has clearly brought some fairly strong weather effects that have weighed on growth, with guidance pointing toward the low end, which would mean a decline on the top line. At this point, how much visibility do you have into this business getting back to growth on the top line in 2025? Thank you.

Stefan Oelrich

executive
#48

Emily, thanks for asking about China. China has clearly been a headache across recent years with VBP. That impact is now largely washing out for our pharma business overall. So at this point I'm seeing slight growth in the first couple of months. But for the first two quarters it's basically level with the prior year. And if no further VBP hits before year-end, we could even see China turn slightly positive.

Rodrigo Santos

executive
#49

And Emily, regarding glyphosate, thank you for asking. On slide 24 of the deck, in the appendix, we have a really good slide about glyphosate that shows some of how glyphosate has performed from 2019 through the 2024 forecast. There you can see that this year glyphosate is going back to its historical level — when it comes to pricing, when it comes to volumes, and when it comes to how we performed as well, when it comes to sales. As you mentioned, it's early to talk about 2025, but we aren't expecting a big change on that front. What we plan to use is the historical pricing we have as the reference for VBP, as we call it in China. So probably, for glyphosate next year, we don't expect a big change unless maybe something happens. But that's roughly what's in our plans. Slide 24 does give somewhat more detail on that. Thank you.

Jost Reinhard

executive
#50

Thanks. So next up we have James Quigley from Goldman Sachs and Richard Vosser from J.P. Morgan. James, go ahead and kick us off.

James Quigley

analyst
#51

Excellent. Thanks for the question. This is James Quigley from Goldman Sachs. First, let's begin with a broad one for 2025 directed at Stefan. You mentioned margin moderation during this year's second half. Yet as we move into 2025, what is your view on how the business will perform? You referenced launch brands offsetting Xarelto, but what about the base business? Could strength in brands such as Mirena and the radiology portfolio offset some of the headwinds affecting other portions of the base business when considering the 2025 growth outlook? Then a second one, also for Stefan. Digging into Nubeqa sales, which are clearly very, very strong this quarter. What are the main drivers here? Is it the US label expansion into the hormone-sensitive setting? Has there been a change in marketing message, or are physicians simply becoming more and more comfortable with Nubeqa's profile relative to the other androgen receptor inhibitors in the space? And just to round off that question, to confirm what Sachin asked, was there any bolus, was there any kind of launch or geographic expansion that produced the strong results this quarter?

James Quigley

analyst
#52

And then when you annualize that, Nubeqa by itself gets us to $1.5 billion. ... Could that happen this year?

Stefan Oelrich

executive
#53

Thanks for those questions. James, you'll appreciate that I won't be providing guidance for 2025 following the second quarter. That said, I believe you raised a couple of solid points that really strike a chord with me. In the US, we're witnessing a rebound in the women's healthcare business during the first half, and that follows what I'd describe as a downturn still tied to COVID. To my mind, Mirena is simply one of those contraceptive choices with the strongest evidence of effectiveness available. So for me, it's no shock that it's recovering, and we ought to see this business keep showing resilience. In radiology, growth has continued through the first half here. I think we're genuinely gaining from solid demographics worldwide that underpin this kind of business, and as the market leader we benefit from that disproportionately. So again, there's no reason for that to shift. So, to your point, I see a fairly resilient base business ahead for Bayer Pharma. Nubeqa — thank you for your enthusiasm about it. Believe me, we share that fully. So there's no bolus that I know of, or any special launch that I'm aware of, but we are seeing dynamic development across nearly every region.

Stefan Oelrich

executive
#54

My sense is that this mostly comes down to doctors growing more at ease prescribing Nubeqa. And clearly, with ARASENS under our belt first and now ARANOTE, we're moving beyond the urologist alone writing the product and into the oncologist setting as well. So a wider prescriber base, with people becoming more comfortable. I'm genuinely seeing a very encouraging trend, and we're certainly hoping it keeps going in the quarters ahead.

Jost Reinhard

executive
#55

Thanks.

James Quigley

analyst
#56

Excellent. Thank you.

Jost Reinhard

executive
#57

Richard, the floor is yours.

Richard Vosser

analyst
#58

Thank you so much for the question. There are two, if I may. First, regarding pharma, Stefan, could we explore a bit further the EYLEA and the eight-milligram launch — what you are observing, and how you expect that to unfold, perhaps in terms of percentage share, over the quarters ahead? Then the second one is for Rodrigo, on pricing dynamics as we move into the second half. I hope you can hear me. How are those going to play out, especially for crop protection? That would be helpful. And perhaps, if you can — I know it is early — in 2025. Many thanks.

Stefan Oelrich

executive
#59

Richard, when I look at EYLEA, obviously the sample of countries where we've launched is limited. We've had successful introductions in Germany, Japan, and Switzerland—our classic first-to-launch markets. I'd say it's within what I expected, and it just supports the overall dynamic we're seeing, where EYLEA is confirmed as the standard of care in this area. And despite other entrants in the class, our volumes haven't gone down at any point, which I think shows you there's room in this marketplace, or that they're taking share from someone other than us. With 8 milligrams, given the strong data we have, I'd expect it to be another reason both to improve price and to maintain positive volume development with EYLEA. So we're feeling quite good about this for the coming years.

Rodrigo Santos

executive
#60

When it comes to crop protection in particular, we anticipate stronger volume growth in the back half of the year. We still expect pressure from generics, and as we planned for this year, we have higher volumes, particularly in Latin America. There's what I mentioned regarding the soybean fungicide franchise, which matters a great deal to us, along with the insecticide Curbix, so that's a major volume driver. That said, let me touch on one point I consider quite important. At the capital market day for crop science, we stressed how much operational excellence matters, and we're seeing that play out this year. You saw Wolfgang's figures too, and this is a good moment for me to underscore that we're working this year to deliver a fourth straight year of core growth. For the core business, our guidance is 1%-4%. We expect to land at the lower end of that range, but again, a fourth consecutive year of growth in the core, and that reflects a mix with a very strong showing in the seed business, soybean included. Our figures and our market research point to us going above 40% share in the U.S., and we'll also see in the second half, to address your question, that soybean performance is consistently very strong later on.

Rodrigo Santos

executive
#61

Yet once more, a really key part of how crop science has done this year — and we're hopeful we can keep delivering on that as we get ready for the big launches ahead, with those 10 blockbusters over the coming 10 years. So, thank you.

Jost Reinhard

executive
#62

Great. Up next we have Falko Friedrichs with Deutsche Bank and Jo Walton with UBS. Falko, go right ahead.

Falko Friedrichs

analyst
#63

Thanks. Am I coming through clearly on your end?

Jost Reinhard

executive
#64

Correct.

Falko Friedrichs

analyst
#65

Thanks. My first question goes to Rodrigo, and it kind of builds on what was asked before. Broadly speaking, for 2025, leaving glyphosate aside, could you talk a bit about what the main volume drivers will be for 2025 across the various product groups? And why do you feel confident that we ought to expect a decent year, with decent volume growth, next year? Then my second question is for Wolfgang, on FX. As things stand today, how much FX risk do you see to this year's guidance? And perhaps you could remind us how strong a natural hedge you have in Brazil. Thank you.

Rodrigo Santos

executive
#66

Honestly, that's a tough one to answer. At 25, it's simply too soon. When we return on Q3, we'll have solid data regarding the 2025 season. You've likely seen a few of the recent reports about U.S. yields coming in strong, which affects overall stock levels and commodity prices toward the end of the season. So as we see it, there's still a bit of pressure on commodity price for 2025. We need to watch that corn-to-soybean ratio. In 2024, conditions favored soybean and were unfavorable for corn, yet that doesn't work well for our portfolio. It's too early to make a call on 2025. Of course, we'll come back with additional detail on Q3, but it will depend heavily on supply and demand as well as the commodity price. Still, today we anticipate some remaining challenges for farmers on commodity price next year. That again requires us to maintain the engine we have—launching new hybrids and new formulations, relying on our innovation, and pricing for value the way we're doing this year.

Rodrigo Santos

executive
#67

Corn prices worldwide are rising by nearly 5%, and that is what underpins the operational excellence we must deliver during these years, when farmers face a tougher market environment. But we will return with far more detail at Q3. Wolfgang?

Wolfgang Nickl

executive
#68

Yes. And Falko, thank you for asking about FX. During this call I noted that our assumptions haven’t changed—that was what we said following Q1—and that represents a fairly substantial headwind. If you run the numbers, it comes to roughly between EUR 1 billion and EUR 1.5 billion on the top line, around EUR 0.5 billion at the EBITDA level, and EUR 0.30 at the EPS level. Broadly, you need to keep in mind that 80% of our revenue is generated outside the Eurozone, while only 60% of our costs sit outside the Eurozone. So we don’t really have a strong natural hedge, and Brazil is definitely not among the countries where we enjoy a good natural hedge. At the revenue level, the Brazilian real is probably the largest impact included in the figures I just cited, followed by Japan, Russia, and still Argentina. That said, I’m fairly confident in the hedging policy we’ve implemented to date, and barring any drastic moves, we feel confident enough to reaffirm our FX guidance. One final point, which also always matters with respect to the balance sheet: we of course monitor the strength of the US dollar, since it affects our net financial debt.

Wolfgang Nickl

executive
#69

Still, judging by all the evidence in front of us, we feel sure about holding it at the Q1 level.

Falko Friedrichs

analyst
#70

Alright. Jo, you’re next. Go ahead, please.

Jo Walton

analyst
#71

Thank you. I have one pharma question, one point of clarification, and a litigation question for Bill. First, regarding Nubeqa, is there any benefit you're observing from the co-pay changes, which are now lower for this rather expensive drug? Are you finding that patients remain on the drug longer? Does that contribute to the sales increase? On Kerendia, if I could also just check, it wasn't on top of standard of care. So just to be clear, what proportion of patients might have taken an SGLT2, so we can see whether this is going to be a better drug than what would probably be the first cheap option for a doctor to go for? And for Bill, you mentioned trying to get a bill through Congress, a farm bill. I just want to understand if you can help us on the level of sort of bipartisan support, you know, the degree to which you've got this, as something that people think is important at congressional level. And if you did get that through, what protection would that provide you from a broad litigation point of view? Thank you.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Bayer Aktiengesellschaft transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Bayer Aktiengesellschaft earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Bayer Aktiengesellschaft or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.